TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00373295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
Study: NCT00315354

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Very low carbohydrate diet
Description: Feeding protocol, all foods prepared in a metabolic kitchen
Study: NCT03418571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171 1.5 mg/kg
Description: ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
Study: NCT00373295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01282450

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study: NCT02861560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dHACM
Description: Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
Study: NCT01323127

Intervention type: PROCEDURE
Intervention: Sagital xrays
Description: 5 xrays will be taken: (1) Upright standing position; (2) Upright, straight chair position; (3) Slouching, straight chair position; (4) Upright, ergonomic chair position; (5) Slouching, ergonomic chair position.
Study: NCT00373295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03635138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metal nanoparticles ( O Zn and Cu)
Description: Np of OZn nanoparticles mixed with dental adhesive

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental Adhesive pure
Description: Dental Adhesive with commercial preparation
Study: NCT01004419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib)
Description: vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faslodex (Fulvestrant)
Description: Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.
Study: NCT02156362

Intervention type: OTHER
Group type: OTHER
Intervention: follow up visit
Description: At least 1 follow up visit per year will be done and an additional visit if needed.
Study: NCT03437434

Intervention type: OTHER
Intervention: Visual Acuity
Description: Ocular Examination
Study: NCT03418571

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered via a single inhalation once daily for 3 consecutive days.
Study: NCT02832583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regenkit BCT-HA Cellular Matrix
Description: To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
Study: NCT01835431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Administered s.c. with the remaining meals. Dose individually adjusted.
Study: NCT00882700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg Capsule (Sandoz, Austria)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
Study: NCT02770261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R208
Description: DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
Study: NCT01835431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
Study: NCT02770261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan32mg
Description: DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Study: NCT02342314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3143753 (Part A)
Description: Administered via SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3185643 (Part B)
Description: Administered via SC injection
Study: NCT02770261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DP-R208 Placebo
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Study: NCT01835431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administered s.c. at meal-times. Dose individually adjusted.
Study: NCT03673722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foods consistent with a MDP
Description: We aim to increase MDP by 3 points, according to a 14-point MEDAS score
Study: NCT05554900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preventive regenerative peripheral nerve interface reconstruction
Description: Each RPNI unit consists of nerve stump and free autologous muscle graft that is cut off from healthy muscle of the amputated limb. The muscle graft is approximately 30×15×5 mm.The ends of the transected nerve are placed within the muscle belly of the free muscle grafts in an orientation that is parallel to the muscle fibers. Next, the nerve is secured distally with 6-0 non-absorbable monofilament sutures in an epimysial-to-epineurial fashion. The nerve is then wrapped around completely via muscle graft and epimysial securing sutures. All RPNI units are placed in areas remote from the surgical incision and from the weight-bearing surface of the limb.
Study: NCT01772225

Intervention type: OTHER
Intervention: Data collection
Description: Medical record abstraction form and patient survey questionnaire.

Intervention type: OTHER
Intervention: Data collection
Description: Medical record abstraction form and patient survey questionnaire.
Study: NCT02177669

Intervention type: OTHER
Intervention: quick Contrast Sensitivity Function test
Study: NCT03153397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutraflora scFOS
Description: prebiotic fiber (Nutraflora scFOS via Vital AF)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osmolite
Description: non-prebiotic fiber containing formula (Osmolite)
Study: NCT02590679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venues-P Valve
Description: a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
Study: NCT03955848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alloreactive NK cell infusion
Description: Alloreactive NK cell infusion
Study: NCT03453060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-WE Thrombin- Dose 1
Description: Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-WE Thrombin- Dose 2
Description: Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-WE Thrombin- Dose 3
Description: Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-WE Thrombin- Dose 4
Description: Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received a single intravenous dose of placebo.
Study: NCT00916604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Three increasing dose-steps with oral suspension, 8 days treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension, 8 days treatment
Study: NCT03378401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octenidinedihydrochlorid
Description: Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
Study: NCT02770261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DP-R208 Placebo
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan32mg Placebo
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan32mg Placebo
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg Placebo
Description: DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg Placebo
Description: DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
Study: NCT03719768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiotherapy
Description: Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks
Study: NCT00926068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HO/03/03 10µg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01272284

Intervention type: DEVICE
Group type: OTHER
Intervention: Altis® Single Incision Sling System (SIS)
Description: The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence.
Study: NCT01450111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 50 mg, tablet, once in the morning on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 100 mg, tablet, once in the morning on Day 1 Lacosamide 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
Study: NCT02342314

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part A and Part B)
Description: Administered via SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part A and Part B)
Description: Administered via SC injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rGlucagon (Part B)
Description: Administered via SC injection
Study: NCT00252161

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy with more than D2 dissection
Description: Gastrectomy with more than D2 dissection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
Description: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
Study: NCT01492517

Intervention type: OTHER
Group type: OTHER
Intervention: Ozone exposure
Description: Exposure to 0.3ppm ozone for 2 hours
Study: NCT03673722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foods consistent with a MDP
Description: We aim to increase MDP by 3 points, according to a 14-point MEDAS score

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: We aim to increase PA to 150 minutes moderate activity per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will be given generic healthy eating advice based
Study: NCT02577302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAN-Stim - Protect CAN-Stim System
Description: CAN-Stim subjects will be implanted unilaterally (implantation side is up to the investigators discretion) with the CAN-Stim System. Subjects will be educated on the use of the transmitter and programmer. Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will continue therapy and followed for a total of 12 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SNS - InterStim® System
Description: Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study.Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will receive a full implant and followed for a total of 12 months.
Study: NCT02725619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PST
Study: NCT02822716

Intervention type: PROCEDURE
Group type: OTHER
Intervention: IRE treatment
Description: The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
Study: NCT01492517

Intervention type: OTHER
Group type: OTHER
Intervention: Diesel exhaust
Description: Diesel exhaust generated from a diesel generator delivered to the exposure at a target concentration of 300 μg/m3

Intervention type: OTHER
Group type: OTHER
Intervention: Ozone18
Description: Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O).
Study: NCT02822716

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Study: NCT03161236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercise program
Description: Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
Study: NCT01492517

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean Air
Description: Exposure to air which has been scrubbed to remove air pollutants including ozone and particles.
Study: NCT03161236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non exercise program
Description: continue usual lifestyle
Study: NCT00139594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: licarbazepine
Study: NCT02609191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body exam using the Discovery A
Description: Whole body exam using the Discovery A machine made by Hologic.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body exam using the Discovery A
Description: Whole body exam using the Discovery A machine made by Hologic.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: First whole body exam using the Stratos DR
Description: First whole body exam using the Stratos DR machine made by the DMS group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: First whole body exam using the Stratos DR
Description: First whole body exam using the Stratos DR machine made by the DMS group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Second whole body exam using the Stratos DR
Description: Second whole body exam using the Stratos DR machine made by the DMS group. This second exam is required for reproducibility purposes.
Study: NCT02754219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin
Description: DPP4-inhibitor, Evogliptin
Study: NCT00620802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGT-2168
Description: (CGT-2168, one capsule each daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix
Description: (clopidogrel, 75 mg)
Study: NCT00544687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-191
Description: topical (mometasone furoate + nortriptyline HCl)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-191
Description: topical (mometasone furoate + nortriptyline HCl)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate
Description: topical mometasone furoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nortriptyline HCl
Description: topical nortriptyline HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Karison® Creme
Description: topical Karison® Creme (clobetasol-17-propinate 0.05%)
Study: NCT01450111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 200 mg, tablet, once in the morning on Day 1 Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with Lacosamide 50 mg tablet once in the morning on day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with Lacosamide 100 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamode 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with Lacosamide 200 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
Study: NCT02495233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: oral
Study: NCT00544687

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical (placebo)
Study: NCT03765021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser
Description: The other side of the face will be randomly assigned to low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
Study: NCT04918914

Intervention type: DRUG
Group type: OTHER
Intervention: Dapsone 100 MG
Description: Dapsone 100-200 md orally daily, along with Cimetadine 400 mg PO TID